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Abstract
Sickle cell nephopathy (SCN) begins early in childhood from failure of urinary concen-
tration (hyposthenuria), albuminuria to hyperfiltration, hematuria and progression to 
falling glomerular filtration to end-stage renal disease and increased mortality. Renal 
involvement is more severe in homozygous individuals (HbSS) than in compound het-
erozygous patients (HbSC). The pathogenesis of SCN is multifactorial from hypoxia, 
acidosis, hemolysis, ischemia-reperfusion injury and albuminuria. The clinical manifes-
tations depend on whether the main pathology is tubular, glomerular or a mixture of 
both abnormalities. This chapter offers a critical review of the recent literature and will 
highlight the pathophysiology, epidemiology, clinical manifestations and management 
of sickle cell nephropathy with particular focus on the major advance in the early diagno-
sis. Learning points: For SCN, the onset of hyperfiltration and albuminuria in infants and 
childhood is an opportunity to intervene early. There is no diagnostic markertest capable 
of detecting the onset of these changes. Moreover there is no reliable therapeutic agent to 
prevent or halt early changes due to SCN. The development of a marker of renal impair-
ment in SCD such as such as Cystatin C assay if validated may be appropriate for wider 
clinical application.
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1. Introduction
Sickle cell disease (SCD) is one of the most frequent genetic disorders in the world. It predomi-
nantly affects people of African descent as well as individuals from the Middle East, India and 
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Mediterranean regions. Recent estimates report about 305,800 babies with SCD are born every 
year in the word and over two-thirds are in sub-Saharan Africa rising to over 404,200 by 2050 
[1, 2]. The disease is associated with a high lifetime morbidity and premature mortality [3], 
as described in the 2013 Global Burden of Disease Study [4]. The age-standardized death rate 
in sickle cell anemia increased from 1990 to 2013 (median change 28) [5]. The World Health 
Organization (WHO) has addressed the significant public health implication of sickle cell 
anemia, urging implementation of equitable and effective programs for the prevention and 
management of SCD [6]. Furthermore, encouragement was provided for the promotion, sup-
port and coordination of much needed research in SCD [6].
The term’sickle cell disease’ refers to all genotypes that cause the clinical syndrome. It occurs 
due to the inheritance of abnormal beta globin S (βS) alleles with the substitution of valine 
for glutamic acid in position 6 of the beta globin; the most common phenotype is homozy-
gous βS/βS which is referred to as sickle cell anemia (SCA). The second most common phe-
notype, hemoglobin SC disease (HbSC), occurs due to co-inheritance of the βS and βC alleles, 
and presents a more moderate phenotype. HbS/β-thalassemia is the co-inheritance of βS with 
a β-thalassemia allele [7], those with a thalassemia null mutation (HbSβ0) presenting with a 
phenotype that is clinically indistinguishable from SCA, whereas individuals with HbSβ+ thal-
assemia have a milder disorder [8]. The resulting sickle hemoglobin (HbS) polymerizes when 
the concentration of its deoxygenated form (deoxyHbS) exceeds a critical threshold. Low oxy-
gen levels, increased acidity and cellular dehydration facilitate the polymerization of HbS and 
the distortion of the red blood cells leading to sickle-shaped erythrocytes [9]. The co-inheri-
tance of genetic factors such as α-thalassemia or hereditary persistence of fetal hemoglobin are 
known to reduce the rate of HbS polymerization [10]. Sickling of red blood cells results in both 
obstruction of blood flow leading to organ and tissue ischemia, and hemolytic anemia [2, 11]. 
Reduced blood flow is mediated via a dynamic interaction between sticky HbS-containing red 
blood cells, white blood cells and the vessel wall [2]. Chronic intravascular hemolysis leads 
to the release of free hemoglobin that sequesters nitric oxide, a potent vasodilator and anti-
inflammatory molecule, leading to vasoconstriction in different organs. Stroke and pulmonary 
hypertension are thought to be consequences of the diminished vascular relaxation caused by 
nitric oxide deficiency [12]. In addition, intravascular hemolysis in SCD leads to high plasma 
levels of cell-free heme and hemoglobin (Hb), sources of redox active iron. Iron-derived reac-
tive oxygen species are implicated in the pathogenesis of numerous vascular disorders includ-
ing atherosclerosis, microangiopathic hemolytic anemia, vasculitis and reperfusion injury [13]. 
Exposure of endothelium to heme greatly potentiates cell death. Recurrent cycles of ischemia-
reperfusion injury in the microvasculature might amplify endothelial dysfunction and further 
organ injury including the stroke, pulmonary hypertension and kidney injury.
2. Sickle cell nephropathy
Renal involvement in SCD is a complex phenomenon resulting from an increased tendency 
of sickling in the renal medulla due to hypoxia, acidosis and hyperosmolar conditions [13]. 
Abnormally, high hemodynamic renal blood flow leads to early onset hypertrophic and 
impaired urinary concentrating ability, distal nephron dysfunction and progressive glo-
merulopathy. The combination of cortical hyperperfusion, medullary hypoperfusion and 
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 vasoconstriction leads to further vasculopathy in the kidney. Sickle cell nephropathy (SCN) is 
a spectrum of changes resulting from a cascade of events occurring in the kidney. This is trig-
gered by RBC vascular occlusion, infarction and reperfusion injury occurring within the renal 
medullar, cortex and collecting system. These may present as hyperfiltration, microalbumin-
uria, impaired urinary concentrating ability complicated by episodes of acute kidney disease 
(AKD) features early in childhood. In young adults, there is progressive increase in albuminuria 
and regression of the glomerular filtration rate (GFR). Further deterioration of renal function 
with the development of chronic kidney disease (CKD) (defined as estimated GFR of less than 
90 ml/min/1.73 m2) eventually leads to end-stage renal disease (ESRD) in adulthood (Figure 1).
2.1. Pathobiology/histology
Early stages of SCN are characterized by glomerular hypertrophy, hemosiderin deposits with 
focal areas of hemorrhage or necrosis. This is followed by interstitial inflammation, edema, 
fibrosis, tubular atrophy and papillary infarcts [14–16]. Some of these features were reported 
in a multi-center, retrospective analysis of renal biopsies of 18 SCD patients (16-HbSS, 1-HbSC, 
1 HbSβ thalassemia) who presented with proteinuria, acute or progressive impairment of 
renal function [17]. The study reported focal segmental glomerulosclerosis (FSGS) in seven 
cases, membranoproliferative glomerulonephritis (MPGN) in five and thrombotic microan-
giopathic glomerulopathy in three; while glomerular hypertrophy with or without mesangial 
hypercellularity was reported in three cases. Furthermore immunofluorescence microscopy 
Figure 1. The pathogenetic processes in the development of sickle cell nephropathy [13].
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in the patients with FSGS-type lesions showed irregular staining for IgM and C3 in areas of 
sclerosis [15, 16, 18]. Complement deposition occur in the glomeruli coinciding with various 
degrees of proteinuria including nephrotic syndrome [19].
2.2. Risk factors for renal impairment in sickle cell disease
2.2.1. Hemolysis and vasculopathy
Hemolysis in SCD leads to release of arginase 1, asymmetric dimethylarginine and adenine 
nucleotides, these promote vasomotor dysfunction and proliferative vasculopathy. Circulating 
hemoglobin and heme both referred to as erythrocytic danger-associated molecular pattern 
(eDAMP) molecules activate endothelial inflammatory and angiogenesis. Hemolysis in SCD 
therefore leads to anemia, increased superoxide anion and reactive oxygen species (ROS) pro-
duction and low ROS scavenging enzymes activity promote oxidative stress-induced vascular 
complications. Itokua et al. reported in their study [20] that albuminuria was associated with 
increased white blood cell (WBC) count and LDH enzyme levels. Oxidative damage may 
alter both the structure and the function of the glomerulus due to its effects on mesangial 
and endothelial cells. Activated circulating white blood cells and platelets express adhesion 
glycoproteins leading to endothelial cell adhesion molecules and endothelial dysfunction.
2.2.2. Endothelin-A receptor antagonismo retards the progression of sickle cell nephopathy
Endothelin-1 (ET-1) is a signaling peptide produced by diverse cell types that exerts its physi-
ologic and pathophysiologic actions by binding to two receptor subtypes, ETA and ETB. ETA 
receptor activation induces vasoconstriction, inflammation and nociception which is abolished 
by ETB activation in some tissues. ETA receptor signaling produces oxidant stress and the 
release of cytokines such as NF-kB activate and promote the production of ET-1, the agonist for 
the ETA receptor. A number of studies have reported increased production of ET-1 in SCD thus 
promoting sickling and tissue injury. Kasztan et al. reported that by blocking ETA receptor, the 
progression of SCN in a murine model of SCD was abolished [21]. The introduction of sickle 
RBCs into murine endothelial cells induces ET-1, leading to ETA-dependent vasoconstriction 
[22, 23]. It has also been shown that plasma ET-1 levels are elevated in patients with SCD during 
steady state periods as well as during acute vaso-occlusive crisis. Conversely, plasma ET-1 lev-
els are decreased in SCD patients treated with hydroxyurea [24]. Elevated ET-1 level in SCD is 
associated with endothelial dysfunction and albuminuria in patients with SCD [25]. Bosentan, a 
dual ETA/ETB receptor antagonist used in murine models, decreases hypoxia-related injury to 
renal vessels and lung inflammation [26]. As it has been shown by Kasztan’ s studies, adminis-
tration of ambrisentan (an ETA receptor antagonist), at the time of weaning and continued for 
10 weeks, prevented glomerular dysfunction, tubulointerstitial inflammation and fibrosis [24]. 
The observations of Kasztan et al. support this speculation as the markedly elevated plasma 
ET-1 levels that occur in this model are normalized by chronic administration of ambrisentan 
[21]. Long-term administration of ambrisentan significantly reduced the degree of iron deposit 
in renal tubules. The reduction in tubular iron deposits suggests that ambrisentan reduces 
hemolysis in murine models. Free heme is a well-known promoter of oxidative stress and the 
generation of proinflammatory species, for example, ROS. Free heme also stimulates the pro-
duction of placenta growth factor (PlGF), an angiogenic growth factor that is implicated in the 
Hematology - Latest Research and Clinical Advances158
pathogenesis of tissue injury in SCD as well as the production of ET-1 [27–29]. NO is a suppres-
sor of ET-1 synthesis and vascular ET-1 production may also increase when the vascular system 
is depleted due to NO binding to HbS plasma. ET-1 causes RBC dehydration by activating the 
Gardos channel present in the plasma membrane of RBCs [30, 31].
2.2.3. Mouse models
Mouse models provide opportunities to explore the mechanisms of globin gene regulation 
and the feasibility of gene therapy for this condition and the molecular basis of end-organ 
damage, including SCN [32]. The use of established mouse models is of invaluable help to 
investigate the pathogenesis of SCD-associated multiple organ complications and to identify 
targets for prevention and therapy.
Several murine models have been developed to mimic human SCD. Of these, the Berkeley model 
(BERK mice) has targeted deletions of murine α and β globins (α−/−, β−/−) with a transgene con-
taining human α, βs, Aγ, Gγ and β globins (Hba0/0 Hbb0/0 TG (Hu-miniLCRα1GγAγδβS) (α−/−, 
β−/−, transgene +); thus, these mice almost exclusively express human sickle hemoglobin [33]. 
The BERK mouse model exhibits a wide spectrum of hematologic and histopathologic find-
ings that are similar to those found in humans with SCD. Erythrocyte sickling is significant 
in BERK mice, and erythrocyte survival is very short resulting in massive amounts of heme 
being released into the plasma. As seen in humans with SCD, BERK mice showed a wide spec-
trum of kidney pathologies such as increased cortical hypertrophy, gross and microscopic 
infarcts, iron deposition, enlarged glomeruli associated with mesangial cell and mononuclear 
cell hypercellularity are observed in kidneys from BERK mice [34].
Another mouse model of SCD, the transgenic SAD mouse bears the human α-globin gene 
and the HbS mutation, βS, as well as βAntilles and βD−Punjab which greatly enhance the tendency of 
its hemoglobin to polymerize [35]. The SAD mice display renal hemosiderosis, microvascu-
lar occlusions, vascular thrombosis, cortical infarcts and papillary necrosis. Most mice show 
glomerular hypertrophy and mesangial sclerosis. The glomerular damage is associated with 
abnormal function, characterized by increased blood urea nitrogen levels and proteinuria 
[35]. The glomerular lesions of SAD mice faithfully mimic sickle cell glomerulosclerosis, the 
most severe renal complication observed in individuals with SCD. Therefore, the SAD mouse 
constitutes a valuable model to investigate the pathophysiology of the thrombotic and glo-
merulosclerotic complications of human SCD. Ischemic injury contributes to end-organ dam-
age and other complications of SCD. Increased sensitivity of tissues in SCD to ischemic insults 
has been demonstrated in SCD mice. As it has been showed by Nath et al., after induction of 
bilateral renal ischemia, transgenic SCD mice exhibited massive vascular congestion, sick-
ling of red blood cells and more prominent capillary congestion in the lungs and heart com-
pared to control mice [36]. These results demonstrated increased susceptibility to vascular 
congestion and to ischemia in tissues from SCD mice, suggesting that ischemic episodes may 
contribute to the renal complications observed in SCD. Abnormal leukocyte-endothelium 
attachment associated with endothelial activation was observed in SCD mice, showing inter-
esting parallels between the vascular injury after reperfusion and kidney damage. In addi-
tion, this study suggested that allopurinol, that prevents ischemia-reperfusion generation of 
reactive oxygen species, might be a potential therapy for SCD [37]. The anti-sickling property 
of fetal hemoglobin was also demonstrated in SCD mice [38]. Patients with SCD suffer from 
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painful crises associated with vaso-occlusion. Increased circulating erythrocyte membrane 
microparticles (MPs) have been associated with occlusion of capillaries. Interestingly, MPs 
triggered immediate renal vaso-occlusion in mice. In vitro studies showed that MPs stimulate 
the production of reactive oxygen species by endothelial cells, stimulate RBC adhesion and 
induce endothelial apoptosis. This work introduced a novel concept that associates the shed-
ding of MPs from sickled RBC with vascular disease [39]. An interaction of free heme with 
TLR4 receptor was shown to mediate the nephrotoxicity of heme, in particular, the effects of 
heme on renal blood flow and inflammatory responses [40].
2.2.4. Development of sickle cell nephropathy from infancy to adulthood
Glomerular changes in SCD occur early in the first decade of life even though SCD patients 
remain asymptomatic. These are characterized by high renal blood flow, hyperfiltration and 
hypertrophy. Current data suggest that infants with SCD develop a hyperfiltration phase, 
which plateaus during early childhood. As early as the first year, renal enlargement is 
observed in correlation to hyperfiltration. Hyperfiltration is a well-known phenomenon in 
SCD even though the pathogenesis and pathophysiology is less well understood. As a result 
of hyperperfusion, increased amount of fluids is presented to the proximal tubule triggering 
more tubular reabsorption of sodium and water in order to restore glomerulotubular bal-
ance. Increased proximal tubular sodium reabsorption is associated with high metabolism 
and adaptive cellular response leading to overall renal enlargement. This complex phenom-
enon might be relevant to the glomerular hypertrophy that occurs in SCD [13]. Some studies 
show that for children with HbSS, there is an age-related increase in the estimated creatinine 
clearance in the first decade of life, with a decline toward normal values in the second decade 
[41–43]. In the study by Etteldorf and colleagues, children with SCD aged 4–11 years had a 
significantly higher mean measured glomerular filtration rate (mGFR) (169 mL/min/1.73 m2) 
than normal controls (128 mL/min/1.73 m2) [44]. In the BABY HUG trial, 176 children aged 
9–19 months had a measured GFR at baseline of 125 mL/min/1.73 m2 [45], which was signifi-
cantly higher than published normal values for the same age group [46].
In a cross-sectional study of 410 patients with SCD aged 2–21 (mean age 11) years, 23% of 
HbSS patients showed elevated urinary albumin excretion (≥30 mg/g), while other investiga-
tors have reported a HbSS prevalence of 16–27% in the childhood SCD population [47–49].
Further progressive kidney injury and CKD is reflected in a declining and abnormally low 
GFR. During adolescence, estimated glomerular filtration rate (eGFR) begins to decline in 
some patients, and aroud 10% of adolescent patients with SCD develop a GFR of <90 mL/
min/1.73 m2 [50]. Similarly, Bodas et al. recently reported a CKD prevalence of 8% in a cohort 
of patients with SCD aged 3–17 years [51].
The prevalence of end-stage renal disease (ESRD) in the pediatric SCD population is also 
not well described; however, childhood SCD accounts for only 0.3% of incident pediatric 
ESRD [52].
Eventually, renal failure develops in early adulthood (median age 23–37 years) in SCA and in 
mid-life (median age 50 years) in HbSC disease.
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2.2.5. Proteinuria and chronic kidney disease
The prevalence of albuminuria in SCD is age dependent. It may be classified as moderately 
increased albuminuria (previous called microalbuminuria)—urine albumin concentration of 
30–300 mg/g creatinine and severely increased albuminuria (macroalbuminuria)—urine albumin 
concentration of 300 mg/g creatinine. The prevalence of albuminuria in the first three decades of 
life is up to 27% increasing to 68% in older SCD patients [13]. The understanding of the evolu-
tion of CKD in SCD is evolving the extent to which moderate albuminuria progresses to severely 
increased albuminuria and the relationship with SCN. The development of SCN is likely due 
to complex interactions between SCD-related risk factors and non-SCD phenotype characteris-
tics. Albuminuria is more likely to occur in patients who express specific single-nucleotide poly-
morphisms in the MYH9 and APOL1 genes, which are associated with an increased risk of CKD 
in African Americans [53]. On the other hand, microdeletions in the gene that encodes α-globin 
(reflecting a form of α-thalassemia trait) leads to a lower prevalence albuminuria [54]. Genetic 
polymorphisms of bone morphogenetic protein receptor 1B also influence GFR in SCD [55, 56]. 
SCD patients with albuminuria have increased levels of urinary excretion of markers of tubular 
injury (KIM-1 and NAG) [57]. The individual contribution of these phenomena to SCN is not clear.
2.2.6. Chronic kidney disease and end-stage renal disease
The reported prevalence of ESRD in SCD varies from 5 to 18% depending on the age of the 
cohort but reamins a significant cause of mortality [58, 59]. Similarly, CKD (defined based on 
eGFR) which is usually diagnosed between 30 and 40 years is also a risk factor death [47, 60]. 
In a recent study in Rio de Janeiro, Brazil, 4.3% of patients admitted with SCD had CKD [61]. 
A lower incidence was observed in a study from Senegal, where CKD was identified in 2.6% 
of 229 adults with SCD [62]. The manifestations of CKD in SCD include hypertension, protein-
uria and anemia. Vaso-occlusive history, legs ulcers, osteonecrosis, retinopathy, proteinuria, 
hematuria, hypertension and severe anemia were all identified as predictive factors for CKD 
in SCD [58, 61, 63]. In a recent study from Nigeria, 50% of SCD patients with proteinuria had 
CKD [64]. Risk factors associated with progression of CKD to ESRD (Table 1) include increased 
blood pressure, low hemoglobin levels, haemolysis, leukocytosis, hematuria, prior vaso-occlu-
sive crisis, the βS Central African Republic (CAR) haplotype, pulmonary hypertension, stroke, 
acute chest syndrome and infection with parvovirus B19 [65–78]. The mean survival of patients 
with ESRD and SCD is estimated to be 4 years, even with dialytic treatment [79].
2.2.7. Urinary concentration abnormalities
The onset of urinary concentration defects begins in early infancy (6–12 months) and may 
account for nocturia, polyuria and enuresis in later childhood. The defect in urinary concen-
tration does not respond to vasopressin but it is reported to improve with chronic blood trans-
fusions in young children [47, 63, 64, 80–83]. Further deterioration of the defect in urinary 
concentration is observed from the second decade of life due to the onset of medullary fibrosis 
and the loss of the collecting ducts system. High HBF levels are associated with better urinary 
concentration [84–86]. There may be a role for drugs therapy that enhance the production of 
HbF such as hydroxyurea and decitabine.
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2.2.8. Urinary acidification deficit
The defect in urinary acidification may be a combination of ischemic changes in the medulla 
and reduced capacity of the collecting duct to maintain hydrogen gradient. It is not clear what 
is responsioble for this defect but it has been suggested a resistance of the distal nephron to 
aldosterone may exist [81, 87].
2.2.9. Hematuria
One of the most frequent featurs of SCN is hematuria which is also found in individuals with 
sickle trait [88], it may be micro or macroscopic and it is usually painless [63, 81]. The meca-
hanism is not well defined but capillary congestion due to vaso-oclusive and ischemic injury 
may account for it. It is reported that the left kidney is more likely to be involved due to the fact 
that the left renal vein is compressed between the aorta and the superior mesenteric artery; also 
referred to as a “nutcracker-like” phenomenon [37]. Hematuria might also be due to renal pap-
illary necrosis from vaso-occlusion of vasa recta but rarely from renal medullary carcinoma [63]. 
Nevertheless it is important to exclude other causes such as urinary tract infections, neoplasms, 
vascular malformations, vasculitis, glomerulonephritis and coagulation disturbances [61, 88].
2.2.10. Sickle cell nephropathy and acute kidney injury
The prevalence of acute kidney injury (AKI) in children with SCD presenting to the hospital 
emergency room may be as high as 17% [89], AKI is underreported in pediatric SCD patients. 
In adults, AKI is reported in 4–10% of patients, and in up to 14% of adults with acute chest 
syndrome. AKI in SCD may also reflect the frequent use of non-steroidal anti-inflammatory 
drugs (NSAIDs) to treat painful crises in this patient population [52]. A recent retrospective 
analysis reported 8% of AKI in 149 pediatric patients admitted for acute chest syndrome using 
the Kidney Disease Improving Global Outcomes (KDIGO) and higher with increased hospital 
Table 1. Risk and protective factors associated with progression of CKD to ESRD.
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length of stay [90]. The true incidence of AKI in pediatric SCD patients may be underestimated 
in retrospective studies [89, 90]. In addition, serum creatinine may be an inaccurate marker of 
renal function in SCD due to the relatively high proximal tubular secretion of creatinine found 
in this population [91]. Interestingly, a recent adult study showed that even in patients with a 
normal creatinine level during a pain crisis, acute tubular injury likely occurs, as evidenced by 
a more than twofold rise in urinary neutrophil gelatinase-associated lipoprotein excretion [92]. 
NSAID use is common in children with SCD [93], without evidence to support its benefit com-
pared to other less nephrotoxic options. Similarly, the use of non-steroid anti-inflammatory 
agents (NSAIDS) in children with SCD hospitalized for various indications, including dehy-
dration due to gastroenteritis, was associated with a significant increase in the incidence of AKI 
[94, 95]. Therefore hemodynamic changes may increase the risk of AKI secondary to NSAIDs, 
Another contributing factor includes potential toxic tubular effects of free hemoglobin during a 
sickle crisis. Some SCD patients with CYP2C9 allele variants that alter NSAID metabolism may 
be at increased risk of toxicity. During vaso-occlusive pain crises and acute chest syndrome, the 
risk of AKI is increased by the drop in hemoglobin leading to hypoxic-ischemic events, hemo-
lysis or inflammation. In murine SCD models, brief episodes of hypoxic-ischemic events pro-
duce profound acute renal injury [36, 96]. The murine model of SCD has shown that an increase 
in hemolysis or exposure to excess cell-free hemoglobin can also lead to renal injury [97].
3. Assessment of kidney function
The gold standard for assessing how well the kidneys are working is direct measurement of the 
GFR. CKD is classified based on the eGFR and the level of proteinuria and helps to risk stratify 
patients (Table 2A and B). In individuals with SCD, a GFR greater than 120 mL/min/1.73 m2 
is an additional indicator of abnormal kidney function. However, direct measurement of GFR 
is invasive and time consuming and so estimations of GFR based on the serum creatinine are 
more commonly used. A number of equations exist, including the `Modification of Diet in 
Renal Disease’ (MDRD), CKD-EPI and Cockcroft-Gault equations [98–100]. Different estimated 
GFR calculations have been compared to the measured GFR in people with HbSS from the 
Caribbean and sub-Saharan Africa, the CKD-EPI equation was found to provide the most accu-
rate estimate in two small studies [101, 102]. In individuals with SCD, increased proximal tubule 
secretion of creatinine results in the serum creatinine level being a poor estimate of GFR [103]. 
The diagnostic performance of cystatin C in comparison to serum creatinine was analyzed in a 
meta-analysis of 46 studies, including children and adults. The data compared correlation coef-
ficients between GFR and the reciprocals of serum creatinine and cystatin C in 3703 participants 
and showed significantly better correlations for cystatin C, suggesting that cystatin is superior 
to serum creatinine for the detection of impaired GFR in cross-sectional studies [104].
Proteinuria, albumin-to-creatinine ratio (ACR) is greater than 2.5 mg/mmol in men or 3.5 mg/mmol 
in women, or a protein-to-creatinine ratio (PCR) is greater than 15 mg/mmol is sufficient for a diag-
nosis of CKD. Proteinuria may be classified as moderately increased albuminuria (3–30 mg/mmol 
creatinine) or severely increased albuminuria (greater than 30 mg/mmol creatinine) [105].
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4. Novel diagnostic and predictive biomarkers of AKI in children
4.1. Biomarkers used in sickle cell disease
New biomarkers are promising for the early detection of renal function loss in patients with 
SCD (Table 3), including cystatin C, plasma neutrophil gelatinase-associated lipocalin (NGAL), 
serum liver fatty acid-binding protein (L-FABP), serum kidney injury marker 1 (KIM-1), 
serum interleukin 18 (IL-18), soluble FMS-like tyrosine kinase-1 (sFLT-1) and N-acetyl-b-d 
glucosaminidase (NAG) [106].
4.1.1. Serum cystatin C
Cystatin C (CysC) or cystatin 3, a protein encoded by the CST3 gene, is mainly used as a bio-
marker of kidney function. Recently, it has been studied for its role in predicting new-onset or 
deteriorating cardiovascular disease (CVD). CysC is a nonglycosylated low molecular weight 
(13 kDa) basic protein that inhibits cysteine proteases and it has been demonstrated its closely 
correlation to glomerular filtration rate (GFR) in children [107]. CysC crosses the glomerular 
membrane, and it is reabsorbed and metabolized in the renal tubules and not returned to 
the bloodstream. It is not secreted by the tubules, even in cases of reduced GFR, and is not 
affected by muscle mass, protein intake, metabolic factors, drugs and inflammatory stimuli. It 
has also been reported that serum CysC correlates with the level of albuminuria [108, 109] and 
its levels well perform as marker of renal function to detect cardiovascular outcome both in 
Table 2. (A) GFR categories in CKD; (B) ACR categories (KDIGO 2012) [105].
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 population-based studies and in patients with non-ST-elevation acute coronary syndrome [110]. 
Therefore CysC is an ideal biomarker for study the renal function in SCD patients which is 
ongoing hemolysis and inflammation secondary to the sickling phenomenon and in which 
creatinine clearance is generally increased and serum creatinine is low. Tantawy et al. [111] 
have found significantly higher serum CysC in patients with SCD compared to healthy con-
trols. In particular, patients of their court of study with nephropathy had higher cystatin levels 
than those without, and a significant positive correlation was found with ACR. The authors 
have demonstrated also that patients with SCD treated with hydroxyurea had lower CysC 
levels than untreated patients, possibly due to the role of hydroxyurea in decreasing inflam-
mation [111]. In agreement with Tantawy’s results, Alvarez et al. [108] examined the value of 
serum CysC as a marker for GFR in small cohort of 20 children with SCD with and without 
albuminuria, compared to serum creatinine and creatinine clearance. The mean GFR derived 
from serum cystatin was significantly different among these subgroups, becoming abnormal 
in the proteinuric cohort (63 mL/min per 1.73 m2), compared to 94 mL/min per 1.73 m2 for the 
microalbuminuric and 103 mL/min per 1.73 m2 for the normal subgroups. Serum creatinine 
or creatinine clearance did not change significantly with the level of albuminuria. The authors 
concluded that serum CysC was higher than serum creatinine in SCD, and this probably 
relates to the fact that serum CysC is not secreted by the kidney, as creatinine. Moreover other 
studies have demonstrated the utility of CysC in patients with SCD. Asnani and Reid [109] 
have proved in 98 adults with SCD that CysC levels were significantly correlated with 
 measured GFR, hemoglobin, serum creatinine, urinary albumin-creatinine ratio (UACR) and 
systolic blood pressure. In addition to urine, screening for albuminuria may help in the diag-
nosis of early renal impairment in the patients with SCD before a significant rise in serum 
Table 3. Novel urinary biomarkers.
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creatinine is observed. Receiver-operating characteristic curve (ROC) analysis has revealed 
that the cut-off value of CysC at 580 ng/mL could differentiate patients having SCD with and 
without nephropathy with 87.8% sensitivity and 84.6% specificity. Further prospective stud-
ies are needed to validate this threshold. On the other hand, Cho et al. [112] have evaluated 
the significance of serum cystatin C levels in pediatric patients with chronic kidney disease 
diagnosed by renal biopsy and showed normal serum creatinine levels. The authors have 
found that 95% of the patients showed only slightly increased cystatin C levels from the upper 
normal limit of the reference range and suggested that mildly increased cystatin C without 
increased creatinine might not have clinical significance.
4.1.2. Urine neutrophil gelatinase-associated lipocalin
As it has been showed in several preclinical gene expression analyses performed in AKI 
murine and human models, neutrophil gelatinase-associated lipocalin (NGAL) gene has been 
revealed the to be one of the most upregulated genes in the kidney soon after an ischemic or a 
nephrotoxic insult [113, 114]. NGAL is filtered across the glomerulus, is reabsorbed in proxi-
mal tubules and its urinary concentration increases early during ischemic insults [115, 116]. 
The NGAL protein is also highly induced in regenerating and recovering kidney tubule cells. 
NGAL binds iron; chelation of toxic iron is an important mechanism that protects the kidney 
tubules from worsening injury. Thus, the biological role of NGAL in AKI is one of enhanced 
tubule cell proliferation and recovery [117]. Measurement of urinary NGAL (uNGAL) has been 
demonstrated to be an early, non-invasive marker of AKI due to a variety of etiologies, such 
as cardiac surgery [118], intravenous contrast administration [119], critical care settings [120] 
and kidney transplantation [121]. NAGL has an enormous dynamic range, responds in a dose-
dependent fashion to injury, responds within 3 h of injury, and responds to a wide range of 
injuries, easy to measure due to the recent availability of clinical platforms including a new 
NGAL dipstick. Thus, uNGAL values may then be used to initiate AKI patient care algorithms 
earlier than serum creatinine alone. Although multiple investigations have demonstrated that 
uNGAL is a promising AKI biomarkers, a study by Sundaram et al. [57] has not showed any 
relationship with albuminuria in patients with SCD. This study has also showed that uNGAL 
levels were significantly subnormal (<50 ng/mL) in most patients with SCA and the overall 
uNGAL in most patients were well below levels usually seen in patients with acute or chronic 
renal injury. The authors have explained the results obtained based on the fact that proximal 
tubular function is supra-normal in SCA, and it is likely that any filtered NGAL may be reab-
sorbed much more efficiently, resulting in subnormal urinary NGAL levels in SN.
4.1.3. Soluble FMS-like tyrosine kinase-1
Soluble FMS-like tyrosine kinase-1 (sFLT-1) is a member of the vascular endothelial growth 
factor receptor family (VEGFR) and has an antiangiogenic effect. Soluble FLT-1 is increased in 
SCD due to its over-expression by vascular endothelial cells, vascular smooth muscles, acti-
vated blood monocytes and proximal tubular cells of the renal epithelia [122]. A recent study 
by Youssry et al. [123] investigated the relationship between serum levels of sFLT-1 and other 
conventional biomarkers of renal damage. The serum level of sFLT-1 in SCD patients was 
significantly higher than controls and its median level showed no significant difference when 
comparing patients with SS and Sβ genotypes, hydroxyurea therapy and iron chelation. On 
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the other hand, the authors have found significant positive correlations between serum levels 
of sFLT-1 and microalbuminuria, LDH and indirect bilirubin. Meanwhile, there were no sig-
nificant correlations between serum levels of sFLT-1 and creatinine, eGFR, serum ferritin and 
erythrocyte sedimentation rate (ESR). This association between sFLT-1 levels and microalbu-
minuria combined with the association of sFLT-1 with soluble vascular cell adhesion molecule 
(VCAM) in prior studies [124], suggests that sFLT-1 may contribute to the pathogenesis of 
albuminuria in SCD by promoting endothelial dysfunction.
4.1.4. Serum liver-type fatty acid-binding protein
Serum liver-type fatty acid-binding protein (L-FABP) is an anti-oxidant, renoprotective mol-
ecule induced in the proximal tubule early after experimental AKI. It has been reported in 
children undergoing cardiopulmonary bypass (CPB), the increase in urinary L-FABP maybe 
occur within 4 h of initiating CPB [125]. However, there are conflicting data about L-FABP, 
such as a prospective multi-center study of 311 children undergoing cardiac surgery did not 
show similar increase in L-FABP [106]. In SCD patients, Sundaram et al. [57] reported that 
urine L-FABP level was highest in the youngest group (6–12 years old) even with little evi-
dence of renal injury. In fact urine L-FABP levels are reduced with increasing albuminuria.
4.1.5. Kidney injury molecule-I
Preclinical studies have identified the kidney injury molecule-I (KIM-1) gene to be induced in 
the proximal tubule cells of ischemic rat kidneys [114]. KIM-1 protein regulates phagocytosis 
of damaged cells and thereby limits injury. An extracellular domain of KIM-1 can be detected 
by enzyme-linked immunosorbent assays and is useful as a urinary biomarker in patients with 
AKI. In fact, in a study conducted by Han WK et al., it was shown that in 40 children under-
going CPB, urinary KIM-1 levels were markedly increased in those who have developed AKI 
[126]. On the other hand, a prospective multi-center study of 311 children undergoing cardiac 
surgery confirmed the delay in upregulation of urinary KIM-1 in AKI patients and showed 
that KIM-1 was not significantly associated with AKI after adjusting for other injury biomark-
ers [127]. This data is in contrast with the results published by Sundaram et al. [57]. Indeed 
when KIM-1 levels, detected in all SCA urine samples, were compared within the different 
albuminuria groups, they were detected at lowest levels in patients with normal albumin-
uria, significantly increased in patients with moderately increased albuminuria and further 
increased in the severely increased albuminuria group, suggesting this may be another bio-
marker of relevance in sickle nephropathy that needs to be confirmed in longitudinal studies.
4.1.6. Interleukin-18
Interleukin-18 (IL-18) represents a proinflammatory cytokine that might worsen the degree 
of AKI. Animal studies have shown that IL-18 is induced in the proximal tubule and detect-
able in the urine following ischemic AKI. Numerous pediatric studies have proved that urine 
IL-18 obtained 6- to 12-h post-CPB moderately predicts AKI [128–131]. Cerqueira et al. [131] 
performed a cross-sectional study composed of 45 SCA patients. They founded that IL-18 
levels were correlated closely with markers of hemolysis, endothelial dysfunction and others 
 cytokines levels. These findings suggest probable influences of IL-18 in the pathophysiology 
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of vascular occlusion in SCA. In a recent article published by Duarte et al. [132], the author 
demonstrated that IL18 is associated with diastolic function in SCD patients, and may be 
involved in the pathogenesis of the disease. Genetic polymorphisms within the IL-18 gene 
regions are also associated with diastolic function in SCD, likely by affecting expression levels 
of the genes [132].
4.1.7. N-acetyl-b-d glucosaminidase
N-acetyl-b-d glucosaminidase (NAG) is a lysosomal enzyme produced in proximal tubular 
epithelial cells. The levels increased during kidney injury, a marker of proteinuria both in 
patients with diabetes and in patients with SCD [115, 133]. Sundaram et al. [57] showed that 
urine NAG activity was higher than baseline levels (>2 U/l) and worse in the presence of 
albuminuria. The elevations in NAG may precede moderately increased albuminuria, a likely 
diagnostic tool for early renal damage.
4.1.8. Transforming growth factor-b1
Transforming growth factor-b1 (TGF-b1) is a potent fibrogenic growth factor that may play 
a significant role in pathogenesis of SN [134]. It is a peptide of low molecular weight and has 
pleiotropic action. In the kidneys, it stimulates fibrogenesis through enhanced production of 
extracellular matrix proteins and nephron loss by various mechanisms, such as apoptosis of 
endothelial cells and podocytes [135]. Whether the urinary levels of TGF-b1 has a diagnostic 
significance in the early prediction of SN in children with SCD is still to be determined [136]. 
However in the article published by Sundaram et al. [57], urinary TGF-β was present at very 
low to undetectable levels in their patient population and showed no association with the 
degree of albuminuria. These data are in contrast with those published by Ghobrial et al. [137]. 
In their study, the authors have found a strong positive correlation between urinary TGF-b1 
and urinary proteins and eGFR in all groups of SCD patients studied.
4.1.9. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio
Neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios, as indicators of sub-
clinical inflammation, rarely were been investigated in SCD patients. Emokpae et al. [138] recently 
reported a positive association between NLR, PLR and the increase of inflammatory markers in 
SCD patients such as C-reactive protein (CRP) and fibrinogen. The highest values of NLR and 
PLR were detected in patients with proteinuria and altered renal function. This data suggest that 
these markers may be predictive of a proinflammatory state with underlying renal damage.
4.2. Biomarkers not been investigated in sickle cell disease
4.2.1. Markers of cell-cycle arrest
Metalloproteinases-2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) have 
been identified as a markers of cell-cycle arrest and are induced in renal tubules  following 
AKI. It is supposed that the resulting cell-cycle arrest then limits proliferation of damaged 
tubule cells. The metabolites of TIMP-2 and IGFBP7 can be measured in the urine. In a small 
study of children undergoing CPB, the urinary TIMP-1/IGFBP7 product was increased 4 h 
post-CPB in children who developed AKI [139].
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4.2.2. Urinary excretion of uromodulin
Urinary excretion of uromodulin (UMOD), also known as Tamm-Horsfall Protein (THP), is 
the most abundant protein excreted in urine. It is a glycoprotein that is expressed in the thick 
ascending limb (TAL) of the loop of Henle [140–143]. It has also several roles in salt trans-
port in the tubules, in the innate immunity and in the protection against kidney stones [144]. 
Recently, UMOD has been studied as a marker of acute renal injury both in mouse models of 
ischemia-reperfusion injury and in studies conducted in adult and pediatric patients prior to 
CPB [140, 143, 145]. These encouraging results suggest the possibility of studying UMOD also 
for the early determination of renal damage in SCD patients.
5. Current treatment
The treatment of renal complication in SCD patients should include an adequate fluid intake in 
order to avoid dehydration due to hyposthenuria. The chronic use of drugs toxic to the kidneys, 
such as non-steroidal anti-inflammatory drugs (NSAIDs) should be avoided due to the potential 
for adverse hemodynamic-related renal function deterioration, precipitation of papillary necro-
sis, and the development of NSAID-associated interstitial nephritis and glomerulonephropathies.
5.1. Treatment of hematuria
Hematuria in SCD is typically self-limited. Patients with hematuria should be advised to 
maintain a high urine output by oral hydration and remain at rest. However, in cases of mas-
sive hematuria, a high urine output should be maintained with combination of isotonic flu-
ids and loop diuretics, and adopt measures to alkalinize urine, with sodium bicarbonate or 
acetazolamide. These measures modify the acid and hypertonic environment of the medullar 
region, which favors erythrocyte dehydration, HbS concentration and its polymerization [80]. 
Patients are advised to maintain a urinary volume of 2–4 L/day. Also blood transfusion may 
be necessary in order to reduce HbS level and sickling [146].
In cases of refractory hematuria, high doses of oral urea may be required to achieve blood 
urea nitrogen levels greater than 100 mg/dL, or treatment with vasopressin or epsilon-amino-
caproic acid (EACA) to promote clotting [147].
5.2. Treatment of proteinuria
The benefits of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor 
blockers (ARB) in slowing kidney disease progression in many situations are well-known. 
Improving nocturia has been reported to be an additional beneficial effect of ACE, presumably 
as a result of reduction in GFR [148]. A recent Cochrane database review, in 2015, reported the 
potential for reduction in albuminuria and proteinuria with the use of captopril in patients 
with SCD compared with those without the disease [148]. However, the administration of 
ACE and ARB should be carried out carefully due to the risk of hypotension and hyperkale-
mia, the latter condition often present in SCD patients.
The use of hydroxyurea (HU) has been suggested to reduce proteinuria and hyperfiltra-
tion as suggested in one prospective study consisting of 26 patients with SCD. However, no 
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effect on microalbuminuria was found [77, 149]. A cross-sectional study of 149 adult patients 
showed that those using hydroxyurea were less likely to exhibit albuminuria (defined as 
urinary urinary-creatinine ratios ≥30 mg/g) [149]. A multi-center trial in infants (mean age 
13.8 months) demonstrated that treatment with hydroxyurea for 24 months did not influence 
the GFR. However, it was associated with better urine-concentrating ability and less renal 
enlargement, suggesting a possible renoprotective effect [41]. In a non-randomized study of 
children with SCD requiring hydroxyurea for standard indications, treatment for 3 years led 
to a mean (standard deviation (SD)) decrease in GFR from 167 (SD 46) mL/min/1.73 m2 to 145 
(SD 27) mL/min/1.73 m2, indicating an improvement in the hyperfiltration [150].
Dietary protein restriction is not recommended, because of the underlying growth failure and 
decreased energy state in most patients with SCD [151].
5.3. Treatment of anemia
The use of multiple blood transfusions demonstrated to restore the urinary concentrating 
ability in children with SCD [152, 153]. One study of 120 children with sickle hemoglobin-
opathies found that chronic red blood cell transfusions before the age of 9 years was protec-
tive against the onset of microalbuminuria [154]. Blood transfusion receives HbS, prevent 
direct sickling in the kidney and vaso-occulsion, reducing glomerular and tubular isch-
emia damage to the kidney. However, the benefits of transfusion therapy must be balanced 
against risks including infections, iron overload, acute or delayed hemolytic transfusion 
reactions [48, 155–158].
5.4. Treatment of end-stage renal disease
Hemodialysis is reportedly the leading form of renal replacement therapy for SCD-ESRD 
patients, as well as peritoneal dialysis and kidney transplantation. Mortality in SCD 
patients is approximately 26% during the first year of therapy for ESRD, nearly threefold 
higher than in ESRD patients without SCD. However, SCD patients who received pre-dial-
ysis nephrology care had a lower death rate than those who did not receive such care [159].
Kidney transplantation may offer survival advantage over dialysis in ESRD. As in the general 
population, allograft survival for patients with ESRD is greater in those with a living donor 
than in those with a deceased donor. The post-transplantation one-year graft survival exceeds 
60–80% [160]. Complications specific to the SCD population include higher infection risk due 
to autosplenectomy and precipitation of sickle cell crises with anemia correction following a 
successful transplant. Kidney transplant may be also complicated by allograft venous throm-
bosis, deep vein thrombosis, and vaso-occlusive crises [63, 161, 162]. Suggested maneuvers to 
decrease the incidence of post-transplant complications in these patients include [63, 163] pre-
operative blood transfusions to decrease hemoglobin S levels, preoperative oxygen supple-
mentation with 40% oxygen, pretransplantation warming of the kidney allograft using 37oC 
saline, intraoperative and postoperative dopamine infusion at 4 μg/kg/min stem cell transplan-
tation remain as the only curative treatment with good result and survival rates around 90% in 
4 years [164, 165].
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6. Conclusions
SCN represents a new challenge in the treatment of acute and chronic complications in 
SCD. The underlying pathophysiology it is not completely understood, but it is already known 
that kidney damage occurs since the first months of life. The onset of hyperfiltration and albu-
minuria is an opportunity to intervene. The lack of diagnostic test capable of detecting the onset 
of symptoms remains a barrier to institute therapy. Furthermore, the absence of therapeutic 
strategy compounds the management of SCN. New markers of renal impairment in SCD such 
as the use of cystatin C assays may become available for community-based screening in order 
to identify patients at risk, to treat them and to improve their survival and quality of life.
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